Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: kymeratx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | $79.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/3/2025 | $60.00 | Neutral → Buy | B. Riley Securities |
| 6/2/2025 | $51.00 | Neutral → Buy | BofA Securities |
| 5/20/2025 | $55.00 | Buy | Stifel |
| 3/13/2025 | $52.00 | Buy | Citigroup |
| 12/10/2024 | $60.00 | Buy | BTIG Research |
| 12/6/2024 | $55.00 | Market Perform | BMO Capital Markets |
| 12/2/2024 | $57.00 | Equal Weight → Overweight | Wells Fargo |
| 11/18/2024 | $65.00 | Overweight | Stephens |
| 9/9/2024 | $60.00 | Outperform | Leerink Partners |